A Phase 1/2 interventional study of D07001-softgel capsules in Gastrointestinal Cancer and Biliary Tract Cancer, sponsored by InnoPharmax Inc.. Completed at 4 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by InnoPharmax Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Gastrointestinal Neoplasms with a site in Taiwan — 8 open to participants now, 14 under way, 4 of them phase 3. Gastrointestinal Neoplasms · Taiwan.
Among the 25 studies in Gastrointestinal Neoplasms with a site in Taiwan, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 1/2, and was the 9th registered.
698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.
Browse Gastrointestinal Neoplasms studies →8 of the 25 studies in Gastrointestinal Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:
Genmab · Sites in Taiwan, United States, Australia and 8 more countries
Ages 18+
Pfizer · Sites in Taiwan, United States, Argentina and 17 more countries
Ages 18+
GlaxoSmithKline · Sites in Taiwan, United States, Australia and 16 more countries
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20–85
DualityBio Inc. · Sites in Taiwan, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 7
First in 2004; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 73 across 497 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 222 across the 21 interventional studies, 106 across the 3 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 25 have an industry lead sponsor. The 10 most frequent:
InnoPharmax Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
InnoPharmax Inc. has 1 study filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastrointestinal Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05150691DualityBio Inc.A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Gastrointestinal Neoplasms with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Part 1: Dose-Escalation Phase (Phase 1b) The primary objective is to assess the safety and tolerability of increasing doses of D07001 softgel in patients with unresectable locally advanced or metastatic gastrointestinal (GI) cancer.
Part 2: Dose-Expansion Phase (Phase 2) The primary objective is to assess the safety and tolerability of D07001 softgel in patients who have achieved stable disease or better following first line chemotherapy or combined chemoradiotherapy (CCRT) for unresectable metastatic or locally advanced biliary tract cancer (BTC)
This open label, multicenter study will be conducted in 2 parts: a dose-escalation phase (Part 1) and a dose-expansion phase (Part 2).
In both Part 1 and Part 2, eligible patients will be assigned to receive oral D07001-softgel on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle (9 doses per cycle).
Part 1: Dose Escalation Phase (Phase 1b) Part 1 of the study will follow a 3+3 dose escalation scheme at predefined dose levels. There will be sequential cohorts of 3 to 6 patients each with increasing doses of 40 mg, 60 mg, 80 mg, 120 mg, and 160 mg per cohort. There will be no intra patient dose escalation. Cycle 1 (21 days) is defined as the dose limiting toxicity (DLT) assessment period.
Part 2: Dose Expansion Phase (Phase 2) In Part 2 of the study, eligible patients will be randomized in a 1:1 ratio to receive D07001-softgel in an open label manner at 1 of the 2 dose levels selected for expansion. Twenty (20) patients will be enrolled to each dose expansion cohort. Patients will be treated until withdrawal from treatment due to disease progression according to RECIST v1.1, withdrawn consent, or when another treatment discontinuation criterion is met. Patients who are discontinued from study drug for reasons other than disease progression or toxicity in the first 2 cycles of Part 2 will be replaced.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 2 only:
Adequate bone marrow function, demonstrated by:
Adequate liver function, demonstrated by:
Adequate renal function, demonstrated by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
Drug: D07001-softgel capsules
higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
Drug: D07001-softgel capsules
Active Ingredient:Gemcitabine hydrochloride
Part 1: Establish the Maximum Tolerated Dose (MTD)
MTD will be defined based on the number of dose limiting toxicities (DLT) in subjects at each dose level. DLT definition: In Part 1 of the study, any of the following AEs occurring during Cycle 1 will be classified as DLTs, if there is a reasonable possibility that it is related to the study drug * Hematologic: * Grade 4 neutropenia lasting \>7 days * Febrile neutropenia (defined as neutropenia Grade ≥3 and a body temp ≥38.3°C) * Grade ≥3 neutropenic infection * Grade 4 anemia * Grade ≥3 thrombocytopenia with bleeding * Grade 4 thrombocytopenia * Non-hematologic: o Grade ≥3 toxicities that are considered clinically significant, except those that have not been maximally treated (e.g., nausea, vomiting, diarrhea\*) or can be easily treated (e.g., electrolyte abnormalities). * Failure to deliver at least 6 of the planned 9 doses during Cycle 1 due to treatment-related toxicities. * Upon the second occurrence of a toxicity leading to a dose hold.
Time frame: During Cycle 1 of treatment (each cycle is 21 days) for each subject
Part 1 : Incidence of Adverse Events (AEs)/ Serious Adverse Event (SAEs)
AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
Time frame: From date of informed consent to 30-day follow-up visit for each subject, an average of 10 months
Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug
To measure ratio of total subjects who experienced the dose modifications including dose reduction, interruption, or discontinuation of study drug due to AEs.
Time frame: First dose through last dose for each subject, an average of 8 months
Part 1: Pharmacokinetics (PK)- Cmax
PK would be analyzed by maximum concentration (Cmax) of dFdC
Time frame: Cycle 1 Days 1 and 15
Part 1: PK- AUC
PK would be analyzed by Area Under Curve (AUC) of dFdC
Time frame: Cycle 1 Days 1 and 15
Part 2: Pharmacokinetics (PK)- Cmax
PK would be analyzed by maximum concentration (Cmax) of dFdC
Time frame: Cycle 1 Days 1, 8, and 15; Cycle 1 Day 15 and Cycle 2 Day 1 for food-effect cohort only
Part 2: PK- AUC
PK would be analyzed by Area Under Curve (AUC) of dFdC
Time frame: Cycle 1 Days 1, 8, and 15; Cycle 1 Day 15 and Cycle 2 Day 1 for food-effect cohort only
| Milestone | Part 1:Dose-Escalation Phase_40mg | Part 1:Dose-Escalation Phase_60mg | Part 1:Dose-Escalation Phase_80mg | Part 1:Dose-Escalation Phase_120mg | Part 1:Dose-Escalation Phase_100mg |
|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 6 | 3 |
| Completed | 3 | 3 | 3 | 6 | 3 |
| Not completed | 1 | 0 | 0 | 0 | 0 |
MTD will be defined based on the number of dose limiting toxicities (DLT) in subjects at each dose level. DLT definition: In Part 1 of the study, any of the following AEs occurring during Cycle 1 will be classified as DLTs, if there is a reasonable possibility that it is related to the study drug * Hematologic: * Grade 4 neutropenia lasting \>7 days * Febrile neutropenia (defined as neutropenia Grade ≥3 and a body temp ≥38.3°C) * Grade ≥3 neutropenic infection * Grade 4 anemia * Grade ≥3 thrombocytopenia with bleeding * Grade 4 thrombocytopenia * Non-hematologic: o Grade ≥3 toxicities that are considered clinically significant, except those that have not been maximally treated (e.g., nausea, vomiting, diarrhea\*) or can be easily treated (e.g., electrolyte abnormalities). * Failure to deliver at least 6 of the planned 9 doses during Cycle 1 due to treatment-related toxicities. * Upon the second occurrence of a toxicity leading to a dose hold.
| mg | Part 1:Dose-Escalation Phase |
|---|---|
| Part 1: Establish the Maximum Tolerated Dose (MTD) | 100 |
AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
| participants | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 |
|---|---|---|---|---|---|
| Related to study drug SAEs | 0 | 0 | 0 | 2 | 1 |
| Related to study drug AEs | 2 | 2 | 3 | 6 | 3 |
| DLTs | 0 | 0 | 0 | 2 | 0 |
To measure ratio of total subjects who experienced the dose modifications including dose reduction, interruption, or discontinuation of study drug due to AEs.
No measurements were reported for this outcome.
PK would be analyzed by maximum concentration (Cmax) of dFdC
| ng/mL | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 13.67 ± 7.58 | 42.97 ± 27.14 | 7.37 ± 5.68 | 37.24 ± 23.84 | 24.05 ± 17.43 |
| Cycle 1 Day 15 | 14.45 ± 13.93 | 12.93 ± 2.84 | 10.66 ± 9.15 | 18.47 ± 13.31 | 13.28 ± 7.92 |
PK would be analyzed by Area Under Curve (AUC) of dFdC
| h*ng/mL | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 12.35 ± 7.12 | 41.14 ± 4.42 | 11.59 ± 8.83 | 62.79 ± 42.10 | 54.40 ± 44.19 |
| Cycle 1 Day 15 | 12.71 ± 13.07 | 19.50 ± 3.74 | 14.05 ± 10.30 | 35.20 ± 33.29 | 36.96 ± 31.35 |
PK would be analyzed by maximum concentration (Cmax) of dFdC
No measurements were reported for this outcome.
PK would be analyzed by Area Under Curve (AUC) of dFdC
No measurements were reported for this outcome.
Collected over The Adverse event information was collected and assessed in relation to baseline for study patients from the first dose of treatment until 30 days after discontinuation of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1:Dose-Escalation Phase Level 1 | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part 1:Dose-Escalation Phase Level 2 | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 1:Dose-Escalation Phase Level 3 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 1:Dose-Escalation Phase Level 4 | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Part 1:Dose-Escalation Phase Level 5 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 2: Dose-Expansion Phase (Phase 2) | — | — | — |
| Event | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 | Part 2: Dose-Expansion Phase (Phase 2) |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/6 | 1/3 | — |
| hepatotoxicityHepatobiliary disorders | 0/4 | 0/3 | 0/3 | 1/6 | 0/3 | — |
| FeverGeneral disorders | 0/4 | 0/3 | 0/3 | 1/6 | 0/3 | — |
| Event | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 | Part 2: Dose-Expansion Phase (Phase 2) |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/4 | 0/3 | 1/3 | 3/6 | 2/3 | — |
| VomitingGastrointestinal disorders | 0/4 | 0/3 | 1/3 | 4/6 | 0/3 | — |
| FaitigueGeneral disorders | 0/4 | 0/3 | 2/3 | 4/6 | 1/3 | — |
| FeverGeneral disorders | 0/4 | 0/3 | 1/3 | 2/6 | 1/3 | — |
| AnorexiaMetabolism and nutrition disorders | 1/4 | 1/3 | 1/3 | 2/6 | 1/3 | — |
| DiarrhoeaGastrointestinal disorders | 0/4 | 1/3 | 0/3 | 2/6 | 1/3 | — |
| ChillsGeneral disorders | 0/4 | 0/3 | 0/3 | 2/6 | 0/3 | — |
| MalaiseGeneral disorders | 0/4 | 0/3 | 1/3 | 1/6 | 0/3 | — |
| Alanine aminotransferase increasedInvestigations | 0/4 | 0/3 | 0/3 | 2/6 | 0/3 | — |
| Aspartate aminotransferase increasedInvestigations | 0/4 | 0/3 | 0/3 | 2/6 | 0/3 | — |
Total 19 subjects
| Age, Continuous(years) | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 67.8 ± 13.52 | 57.7 ± 10.69 | 54.7 ± 13.01 | 55.5 ± 10.88 | 55.7 ± 15.50 | 58.3 ± 12.14 |
| Sex: Female, Male(Participants) | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 1 | 1 | 1 | 4 |
| Male | 3 | 3 | 2 | 5 | 2 | 15 |
| Race/Ethnicity, Customized(Participants) | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 | Total |
|---|---|---|---|---|---|---|
| Asian | 4 | 3 | 3 | 6 | 3 | 19 |
| Region of Enrollment(participants) | Part 1:Dose-Escalation Phase Level 1 | Part 1:Dose-Escalation Phase Level 2 | Part 1:Dose-Escalation Phase Level 3 | Part 1:Dose-Escalation Phase Level 4 | Part 1:Dose-Escalation Phase Level 5 | Total |
|---|---|---|---|---|---|---|
| Taiwan | 4 | 3 | 3 | 6 | 3 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Dec 2020, 28 months.
Results were first posted in Nov 2023, 2 years 10 months after primary completion.
Of 36 phase 1/2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InnoPharmax Inc.